Jazz Pharmaceuticals on June 22 Received FDA Orphan for their Treatment of Acute Lymphoblastic Leukemia
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=773420
Amgen Announced Approval Of Aimovig In Japan For The Suppression Of Onset Of Migraine Attacks In Adults
Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Aimovig® (erenumab) for the suppression of onset of migraine attacks in adults.
AstraZeneca Announced Orpathys Approved in China for Lung Cancer
AstraZeneca (NYSE: AZN) and HUTCHMED's (NASDAQ: HCM) Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior syste
Teva Announces Its Launch Of Generic PERFOROMIST, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used To Treat Chronic Obstructive Pulmonary Disease (COPD), In The U.S.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced its U.S. launch of the first generic version of twice daily PERFOROMIST®,formoterol fumarate
DermaTech Reports Partnership With University Of Barcelona For Research Study On Atopic Dermatitis, Psoriasis, No Terms Disclosed
DermTech, Inc. (NASDAQ:DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today a collaboration with researchers from the University of
Sorrento Therapeutics Is Forming Pennant Pattern: Technical Levels To Watch
Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares moved higher Tuesday after the company announced Phase 2 Abivertinib clinical studies have completed patient enrollment in the U.S. and Brazil. The company is expecting top-line clinical data at the end of the third quarter.
Halozyme Announces Janssen Receives European Marketing Authorizations For DARZALEX (daratumumab) Subcutaneous Formulation For Newly Diagnosed Systemic Light-Chain Amyloidosis And Pre-Treated Multiple Myeloma
Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that the European Commission (EC) has granted the Janssen Pharmaceutical Companies of Johnson & Johnson two marketing authorizations for the subcutaneous
Biofrontera Stock Moves Higher On Outlining Clinical Update
Biofrontera AG (NASDAQ:BFRA) has provided an update on two submissions to the FDA, enabling the simultaneous use of up to three…